Long-term Effects of Low Calcium Dialysates on the Serum Calcium Levels During Maintenance Hemodialysis Treatments: A Systematic Review and Meta-analysis

Overview

Journal Sci Rep

Specialty Science

Date 2018 Mar 30

PMID 29593281

Citations 9

Authors

Masahiro Yoshikawa

Osamu Takase

Taro Tsujimura

Etsuko Sano

Matsuhiko Hayashi

Tsuyoshi Takato

Keiichi Hishikawa

Affiliations

Soon will be listed here.

Abstract

Hypercalcemia and hyperparathyroidism in patients receiving maintenance hemodialysis (MHD) can cause the progression of cardiovascular diseases (CVD) and mineral bone disorders (MBD). The KDIGO recommends the dialysates with a calcium (Ca) concentration of 1.25-1.5 mmol/L for MHD treatments, but the optimal concentration remains controversial. Here, we conducted a systematic review and a meta-analysis of seven randomized controlled trials examining a total of 622 patients to investigate the optimal concentration for MHD for 6 months or longer. The dialysates with a low Ca concentration (1.125 or 1.25 mmol/L) significantly lowered the serum Ca and raised the intact parathyroid hormone levels by 0.52 mg/dL (95% confidence interval, 0.20-0.85) and 39.59 pg/mL (14.80-64.38), respectively, compared with a high Ca concentration (1.50 or 1.75 mmol/L). Three studies showed that a low concentration was preferred for lowering arterial calcifications or atherosclerosis in different arteries, but one study showed that coronary arterial calcifications increased with a low concentration. Two studies showed contradictory outcomes in terms of MBD. Our meta-analysis showed that a dialysate with a low Ca concentration lowered the serum Ca levels in patients receiving long-term MHD, but further studies are needed to determine the optimal Ca concentration in terms of CVD and MBD.

Citing Articles

Hemodialysis Procedures for Stable Incident and Prevalent Patients Optimize Hemodynamic Stability, Dialysis Dose, Electrolytes, and Fluid Balance.

Stuard S, Ridel C, Cioffi M, Trost-Rupnik A, Gurevich K, Bojic M J Clin Med. 2024; 13(11).

PMID: 38892922 PMC: 11173331. DOI: 10.3390/jcm13113211.

Risk of cardiovascular death in patients with hepatocellular carcinoma based on the Fine-Gray model.

Zhang Y, Liu Z, Liu Z, Bai Y, Chi H, Chen D World J Gastrointest Oncol. 2024; 16(3):844-856.

PMID: 38577452 PMC: 10989395. DOI: 10.4251/wjgo.v16.i3.844.

The impact of low and high dialysate calcium concentrations on cardiovascular disease and death in patients undergoing maintenance hemodialysis: a systematic review and meta-analysis.

Kamei K, Yamada S, Hashimoto K, Konta T, Hamano T, Fukagawa M Clin Exp Nephrol. 2024; 28(6):557-570.

PMID: 38396314 DOI: 10.1007/s10157-024-02460-3.

Magnesium inhibits peritoneal calcification as a late-stage characteristic of encapsulating peritoneal sclerosis.

Aihara S, Yamada S, Matsueda S, Nagashima A, Torisu K, Kitazono T Sci Rep. 2023; 13(1):16340.

PMID: 37770630 PMC: 10539370. DOI: 10.1038/s41598-023-43657-y.

Dialysate calcium, alfacalcidol, and clinical outcomes: A post-hoc analysis of the J-DAVID trial.

Iseki K, Kabata D, Shoji T, Inaba M, Emoto M, Mori K PLoS One. 2022; 17(9):e0273195.

PMID: 36070301 PMC: 9451061. DOI: 10.1371/journal.pone.0273195.

References

He Z, Cui L, Ma C, Yan H, Ma T, Hao L . Effects of Lowering Dialysate Calcium Concentration on Carotid Intima-Media Thickness and Aortic Stiffness in Patients Undergoing Maintenance Hemodialysis: A Prospective Study. Blood Purif. 2016; 42(4):337-346. DOI: 10.1159/000450747. View

Tentori F, Wang M, Bieber B, Karaboyas A, Li Y, Jacobson S . Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephrol. 2014; 10(1):98-109. PMC: 4284424. DOI: 10.2215/CJN.12941213. View

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

Chertow G, Block G, Correa-Rotter R, Drueke T, Floege J, Goodman W . Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012; 367(26):2482-94. DOI: 10.1056/NEJMoa1205624. View

Lu J, Yi Y, Xiong Z, Cheng X, Hu J, Hang H . The Study of Low Calcium Dialysate on Elderly Hemodialysis Patients with Secondary Hypoparathyroidism. Blood Purif. 2016; 42(1):3-8. DOI: 10.1159/000443470. View

Ok E, Asci G, Bayraktaroglu S, Toz H, Ozkahya M, Yilmaz M . Reduction of Dialysate Calcium Level Reduces Progression of Coronary Artery Calcification and Improves Low Bone Turnover in Patients on Hemodialysis. J Am Soc Nephrol. 2015; 27(8):2475-86. PMC: 4978036. DOI: 10.1681/ASN.2015030268. View

Moldovan D, Rusu C, Kacso I, Potra A, Patiu I, Gherman-Caprioara M . Mineral and bone disorders, morbidity and mortality in end-stage renal failure patients on chronic dialysis. Clujul Med. 2016; 89(1):94-103. PMC: 4777475. DOI: 10.15386/cjmed-515. View

Ketteler M, Block G, Evenepoel P, Fukagawa M, Herzog C, McCann L . Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. Kidney Int. 2017; 92(1):26-36. DOI: 10.1016/j.kint.2017.04.006. View

Shahapuni I, Mansour J, Harbouche L, Maouad B, Benyahia M, Rahmouni K . How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?. Semin Dial. 2005; 18(3):226-38. DOI: 10.1111/j.1525-139X.2005.18318.x. View

10.

Holgado R, Haire H, Ross D, Sprague S, Pahl M, Jara A . Effect of a low calcium dialysate on parathyroid hormone secretion in diabetic patients on maintenance hemodialysis. J Bone Miner Res. 2000; 15(5):927-35. DOI: 10.1359/jbmr.2000.15.5.927. View

11.

Kurz P, Monier-Faugere M, Bognar B, Werner E, Roth P, Vlachojannis J . Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int. 1994; 46(3):855-61. DOI: 10.1038/ki.1994.342. View

12.

Jadoul M, Albert J, Akiba T, Akizawa T, Arab L, Bragg-Gresham J . Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2006; 70(7):1358-66. DOI: 10.1038/sj.ki.5001754. View

13.

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339:b2700. PMC: 2714672. DOI: 10.1136/bmj.b2700. View

14.

Daugirdas J, Chertow G, Larive B, Pierratos A, Greene T, Ayus J . Effects of frequent hemodialysis on measures of CKD mineral and bone disorder. J Am Soc Nephrol. 2012; 23(4):727-38. PMC: 3312501. DOI: 10.1681/ASN.2011070688. View

15.

Cao X, Zhou J, Cai G, Ding R, Tang L, Wu D . Long term effects on mineral and bone metabolism by low versus standard calcium dialysate in peritoneal dialysis: a meta-analysis. Int J Clin Exp Med. 2015; 8(2):2031-7. PMC: 4402780. View

16.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

17.

Gotch F, Kotanko P, Thijssen S, Levin N . The KDIGO guideline for dialysate calcium will result in an increased incidence of calcium accumulation in hemodialysis patients. Kidney Int. 2010; 78(4):343-50. DOI: 10.1038/ki.2010.157. View

18.

Spasovski G . Advances in pharmacotherapy for hyperphosphatemia in renal disease. Expert Opin Pharmacother. 2015; 16(17):2589-99. DOI: 10.1517/14656566.2015.1092521. View

19.

Haris A, Sherrard D, Hercz G . Reversal of adynamic bone disease by lowering of dialysate calcium. Kidney Int. 2006; 70(5):931-7. DOI: 10.1038/sj.ki.5001666. View

20.

Fournier A, Moriniere P, Ben Hamida F, el Esjer N, Shenovda M, Ghazali A . Use of alkaline calcium salts as phosphate binder in uremic patients. Kidney Int Suppl. 1992; 38:S50-61. View